The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab.
| Autor: | Savoldy MA; Dermatology, University of South Florida Morsani College of Medicine, Tampa, USA., Tadicherla T; Dermatology, University of South Florida, Tampa, USA., Moureiden Z; Dermatology, University of South Florida, Tampa, USA., Ayoubi N; Dermatology, University of South Florida Morsani College of Medicine, Tampa, USA., Baldwin BT; Dermatology, James A. Haley Veterans' Hospital, Tampa, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Oct 21; Vol. 14 (10), pp. e30541. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.30541 |
| Abstrakt: | Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 2019 (COVID-19) vaccination. This case was refractory to topical steroids and immunosuppressants. However, it responded to treatment with dupilumab, a monoclonal antibody therapy. Dupilumab is classically indicated for the treatment of asthma, eosinophilic esophagitis, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. We highlight the importance of considering the off-label use of dupilumab and its success in treating BP. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Savoldy et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|